Expression of EZH2, a transcriptional target of MYCN, is associated with neuroblastoma outcome, and inhibition of this histone methyltransferase by genetic or pharmacologic means, leads to neuroblastoma growth inhibition43,44,52–54. The gene discussed is MYCN; the disease is neuroblastoma.